title: Feasibility of intravenous glucose tolerance testing prior to puberty.
abstract: OBJECTIVE
  1) Report the feasibility of completing the 180-minute Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT) in healthy weight, overweight and obese pre-pubertal children and, 2) describe the finalized FSIVGTT protocol after addendums were implemented to decrease the frequency of mild adverse events and improve test completion rates.
  
  
  METHODS
  Insulin sensitivity was determined by FSIVGTT.
  
  
  RESULTS
  FSIVGTT was attempted in a total of 22 study participants. Insulin sensitivity was successfully assessed in 15 study participants (8 males, 7 females, 10 Caucasian, 4 African American, 1 Pacific Islander, age range 7-9 years). Mean insulin sensitivity was 15.1+/-9.8 (mmicro/l)(-1) min(-1) range 4.4-43.2 (mmicro/l)(-1) min(-1). However, seven study participants experienced mild adverse events of hypoglycemia. Several addendums were made to the FSIVGTT protocol to ensure study participants' comfort and safety, and to decrease the frequency of mild adverse events and increase test completion rates.
  
  
  CONCLUSIONS
  Addendums made to FSIVGTT protocol allowed successful completion of FSIVGTT in 15 (68%) of the 22 children. These results demonstrate that FSIVGTT is challenging, yet feasible in healthy lean and obese pre-pubertal children.
authors: Louisiana State University School of Public Health, New Orleans, LA 70112, USA.
authors: Connie L
authors: CL
authors: Tompkins
authors: William
authors: W
authors: Cefalu
authors: Eric
authors: E
authors: Ravussin
authors: Michael
authors: M
authors: Goran
authors: Arlette
authors: A
authors: Soros
authors: Julia
authors: J
authors: Volaufova
authors: Alfonso
authors: A
authors: Vargas
authors: Melinda S
authors: MS
authors: Sothern
mesh_terms: D001741:Black or African American; D001786:Blood Glucose / Q000378:metabolism*; D002648:Child; D003430:Cross-Sectional Studies; D005240:Feasibility Studies; D005260:Female; D005947:Glucose / Q000008:administration & dosage / Q000009:adverse effects; D005951:Glucose Tolerance Test; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007262:Infusions, Intravenous; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects; D007333:Insulin Resistance; D008145:Louisiana; D008297:Male; D044468:Native Hawaiian or Pacific Islander; D009765:Obesity / Q000097:blood* / Q000208:ethnology / Q000503:physiopathology; D050177:Overweight / Q000097:blood* / Q000208:ethnology / Q000503:physiopathology; D011237:Predictive Value of Tests; D046468:Sexual Development; D013997:Time Factors; D044465:White People
chemical_list: D001786:Blood Glucose; D007328:Insulin; D005947:Glucose